Mirador Therapeutics
Unknown, Bahamas · Biotechnology · 35 employees
Mirador is a next-generation precision medicine company focused on immunology and inflammation. The company’s Mirador360 TM precision development engine leverages the latest advances in human genetics and cutting-edge data science to rapidly advance new precision medicines for patients living with chronic immune-mediated inflammatory and fibrotic diseases.
Funding history
- Series series b — $250.0M — Jan 2026
- Funding Round — $333.0M — Apr 2024
- Funding Round — $80.0M — Apr 2024
- Series series a — $400.0M — Mar 2024
Recent signals
- Jan 11, 2026: Raised $250.0M in Series series b
- Sep 17, 2024: Mirador Therapeutics Appoints Gregg Gilbert as Chief Financial Officer
- Apr 03, 2024: Raised $333.0M
- Apr 03, 2024: Raised $80.0M
- Mar 21, 2024: Raised $400.0M in Series series a
See plans & pricing → Track Mirador Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.